leisure time -WSS

leisure time

author：entertainment 2025-09-29 01:36:45 - browse：1

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： John Green on his newest strategy for fighting tuberculosis

Wikipedia

WSS

Medicare coverage of Wegovy, once blocked, now looks possible

In key trial, Verve's treatment lowers cholesterol levels in patients

Boston's new lab space is opening empty

Medicare coverage of Wegovy, once blocked, now looks possible

Astellas still sees hope in its gene therapy after four deaths

As AI in medicine takes off, can 'human in the loop' prevent harm?

hotspot

leisure time

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD podcast: A CRISPR milestone, biotech mixology

New air purifier tech could be key to improving indoor air quality

John Green on his newest strategy for fighting tuberculosis

Trump demands the U.S. pay no more for drugs than other countries … again

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Drug repurposing or repositioning? The language matters

Childhood cancer progress stalls for Black, Hispanic kids: Report

Heart attack and stroke risk calculators need revising

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

hotspot

Anthos stroke drug appears safer than common blood thinner

Does good food count as health care? Study aims to find out

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Astellas still sees hope in its gene therapy after four deaths

Does good food count as health care? Study aims to find out

Childhood cancer progress stalls for Black, Hispanic kids: Report

explore

hotspot

Wikipedia

focus